BeneVir Biopharm, Inc., a biotechnology company developing a pipeline of cancer immunotherapies, today announced it closed a Series A investment round with Pansend, LLC, an indirect wholly owned subsidiary of HC2 Holdings, Inc. (OTCQB: HCHC).
BeneVir’s core technology was licensed from New York University (NYU) and originally developed by Ian J. Mohr, Ph.D., NYU Langone Medical Center.
{iframe}http://www.businesswire.com/news/home/20141119005115/en/BeneVir-Biopharm-Announces-Investment-HC2’s-Subsidiary-Pansend#.VGym9lfF8fQ{/iframe}